Varney and colleagues reported that small-molecule antagonists suppress the activities of CXCR1 and CXCR2 and block the recruitment of neutrophils by the CXCL/CXCR1/2 axis, which results in the decreased neovascularization and increased apoptosis of malignant cells, and finally inhibits the liver metastases of colon cancer [142]. The gene discussed is CXCR2; the disease is malignant colon neoplasm.